While there is good evidence demonstrating the role of NPM1c mutations and other genetic lesions in blocking AML cell differentiation, thePML-RARA fusion subset is diagnostic for a specific subset of AML known as acute promyelocytic leukemia (APL). Here, RARA is linked to acute myeloid leukemia.